Bright Minds Biosciences Announces Findings From Its DBA/2 Mouse Model Study Evaluating BMB-101; Demonstrated A Complete Elimination Of Drop Attacks; Findings Highlight BMB-101's Potential To Address Critical Gaps In SUDEP Prevention

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model -

- The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) -

- Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention -

NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Company's novel scaffold 5-HT2C Gq-protein biased agonist, demonstrated a complete elimination of drop attacks in the DBA/2 mouse model.